Submitted by Anonymous (not verified) on 11 October 2023 - 15:45
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms, Date of authorisation: 04/04/2022, Revision: 2, Status: Authorised
Source: